Alluvi, previously BI 4744, represents a promising advance in obesity care. This dual activator targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates remarkable https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/